Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic vs. therapeutic enoxaparin in severe COVID-19
IRCT20220412054515N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Started May 2022; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20220412054515N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220412054515N1.